Abstract
Background: Globus sensations, hoarseness and chronic cough are suggested to be atypical manifestations of Gastroesophageal Reflux Disease (GERD). The aim of the study was to investigate whether combined pH-metry and multichannel intraluminal impedance monitoring increases the diagnostic yield. Methods: 41 patients with atypical GERD symptoms were included in the study. Globus sensation was the dominant symptom in 23 patients (56.1%). The remaining 18 patients (43.9%) complained mainly about hoarseness or chronic cough. All patients were examined by endoscopy, dual-channel pH-metry and impedance monitoring off-therapy with proton pump inhibitors (PPI). Diagnostic yield of the respective method was determined. Results: A total of 26 patients (63.4%) had pathological findings in any method. The highest diagnostic yield was achieved by combined 24-h pH-metry/impedance measurement (61.0%), followed by solely impedance measurement (48.8%), distal pH-metry (29.3%), endoscopy (22.8%) and proximal pH-metry (17.1%). All patients with a positive PPI-test and 25% of patients (5/20) with a negative PPI-test had a pathological result in pH-metry/impedance. Conclusion: Multichannel intraluminal impedance monitoring increases the diagnostic yield for objective detection of atypical manifestation of GERD. Combined 24-h pH-metry/impedance measurement has the best diagnostic yield for detection of gastroesophageal reflux and has therefore the potential to represent a new diagnostic gold standard.
Journal Section:
Original Paper
References
1.
Klauser AG, Schindlbeck NE, Müller-Lissner SA: Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205–208.
[PubMed]
2.
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–1456.
[PubMed]
3.
Ford CN: Evaluation and management of laryngopharyngeal reflux. JAMA 2005;294:1534–1540.
[PubMed]
4.
Vaezi MF: CON: Treatment with PPIs should not be preceded by pH monitoring in patients suspected of laryngeal reflux. Am J Gastroenterol 2006;101:8–10.
[PubMed]
5.
Belafsky PC: PRO: Empiric treatment with PPIs is not appropriate without testing. Am J Gastroenterol 2006;101:6–8.
[PubMed]
6.
Koufman JA, Aviv JE, Casiano RR, Shaw GY: Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg 2002;127:32–35.
[PubMed]
7.
Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley A, Hwang C, Sostek MB, Shaker R: Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254–260.
[PubMed]
8.
Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E: Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol 2006;101:1972–1978.
[PubMed]
9.
Steward DL, Wilson KM, Kelly DH, Patil MS, Schwartzbauer HR, Long JD, Welge JA: Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg 2004;131:342–350.
[PubMed]
10.
Merati, AL, Lim HJ, Ulualp SO, Touhill RJ: Meta-analysis of upper probe measurements in normal subjects and patients with laryngopharyngeal reflux. Ann Otol Rhinol Laryngol 2005;114:177–182.
[PubMed]
11.
Issing, WJ, Karkos PD, Perreas K, Folwacny, Reichel O: Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux. J Laryngol Otol 2004;118:845–848.
[PubMed]
12.
Vaezi MF, Schroeder PL, Richter JE: Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. Am J Gastroenterol 1997;92:825–829.
[PubMed]
13.
Noordzij JP, Khidr A, Desper E, Meek RB, Reibel JF, Levine PA: Correlation of pH probe-measured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. Laryngoscope 2002;112:2192–2195.
[PubMed]
14.
Anandasabapathy S, Jaffin BP: Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy. Ann Otol Rhinol Laryngol 2006;115:563–570.
[PubMed]
15.
Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398–1402.
[PubMed]
16.
Silny J: Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991;3:151–162.
17.
Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, Janssen J: Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588–1598.
[PubMed]
18.
Shay S, Tutuian R, Sifrim D, Vela M, Wise J, Balaji N, Zhang X, Adhami T, Murray J, Peters J, Castell D: Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004;99:1037–1043.
[PubMed]
19.
Bredenoord AJ, Weusten BL, Timmer R, Conchillo JM, Smout AJ: Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol 2006;101:453–459.
[PubMed]
20.
Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Verin E, Galmiche JP, Sifrim D: Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956–1963.
[PubMed]
21.
Ceccatelli P, Mariottini M, Agnolucci A, Lagana C, Angioli D: Acid exposure of proximal esophagus in healthy subjects. Minerva Gastroenterol Dietol 1998;44:129–134.
[PubMed]
22.
Shaker R, Bardan E, Gu C, Kern M, Torrico L, Toohill R: Intrapharyngeal distribution of gastric acid refluxate. Laryngoscope 2003;113:1182–1191.
[PubMed]
23.
McCollough M, Jabbar A, Cacchione R, Allen JW, Harrell S, Wo JM: Proximal sensor data from routine dual-sensor esophageal pH monitoring is often inaccurate. Dig Dis Sci 2004;49:1607–1611.
[PubMed]
24.
Johnston N, Bulmer D, Gill GA, Panetti M, Ross PE, Pearson JP, Pignatelli M, Axford SE, Dettmar PW, Koufman JA: Cell biology of laryngeal epithelial defenses in health and disease: further studies. Ann Otol Rhinol Laryngol 2003;112:481–491.
[PubMed]
25.
Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE: The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002;16:564–579.
[PubMed]
26.
Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO: Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006;93:1483–1487.
[PubMed]
27.
Chila A, Agrawal A, Castell DO: Combined multichannel intraluminal impedance and pH esophageal testing compared to pH alone for diagnosing both acid and weakly acidic gastroesophageal reflux. Clin Gastroenterol Hepatol 2007;5:172–177.
[PubMed]
28.
McCollough M, Jabbar A, Cacchione R, Allen JW, Harrell S, Wo JM: Proximal sensor data from routine dual-sensor esophageal pH monitoring is often inaccurate. Dig Dis Sci 2004;49:1607–1611.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
